1. bookVolume 26 (2020): Issue 3 (August 2020)
Journal Details
License
Format
Journal
First Published
16 Feb 2013
Publication timeframe
4 times per year
Languages
English
access type Open Access

The Efficiency of the Fight Against HIV, in Constanta, from the Perspective of Neurological Complications

Published Online: 13 Sep 2021
Page range: 126 - 130
Journal Details
License
Format
Journal
First Published
16 Feb 2013
Publication timeframe
4 times per year
Languages
English
Abstract

In order to control and end the AIDS epidemic, we all need to hit the 0-0-0 target. That means 0 HIV infections, 0 mortality caused by AIDS and 0 discrimination. We performed a retrospective observational analytical study on 166 HIV positive patients with a neurological complication, diagnosed between June 2012 and June 2020, in Clinical Infectious Diseases Hospital of Constanta. We collected data from the observational charts that revealed if the patient was known with HIV infection at the time of the neurological complication diagnosis, information about the treatment (how many treatment regimens, classes of antiretroviral drugs, CNS Penetration-Effectiveness Rank), treatment compliance. The patients were divided into two groups: first group “opportunistic infections (OI)” and second group “other neurological conditions (ONC)”. 16 patients (9,6%) have the neurological condition as first manifestation of HIV infection. Opportunistic infections, correlated with a poor immunological status continue to have a high percentage (46,98%) of neurological complications, being associated with a poor treatment compliance (p<0,001). Integrase inhibitors were associated, in this study, more with opportunistic infections and less with other neurological conditions (OR=2,885; 95% IC), this finding needs further research. Long term survivors have problems with treatment compliance manifesting treatment fatigue, even if they have treatment regimens with good CNS penetrability. Poor compliance is associated with high risk of opportunistic infections and opportunistic infections have a higher mortality than other neurological complications. Our task for the future is to find ways to improve treatment adherence in order for HIV patients to have a better and longer life.

Keywords

1. Joseph J, Cinque P, Colosi D, Dravid A, Ene L, Fox H, et al. Highlights of the Global HIV-1 CSF Escape Consortium Meeting, 9 June 2016, Bethesda, MD, USA. Vol. 2, Journal of virus eradication. 2016. p. 243–50. Search in Google Scholar

2. Letendre SL, Ellis RJ, Ances BM, McCutchan JA. Neurologic complications of HIV disease and their treatment. Top HIV Med. 2010;18(2):45–55. Search in Google Scholar

3. Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, et al. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008 Jan;65(1):65–70. Search in Google Scholar

4. Marra CM, Zhao Y, Clifford DB, Letendre S, Evans S, Henry K, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS. 2009 Jul;23(11):1359–66. Search in Google Scholar

5. Bacellar H, Muñoz A, Miller EN, Cohen BA, Besley D, Selnes OA, et al. Temporal trends in the incidence of HIV-1-related neurologic diseases: Multicenter AIDS Cohort Study, 1985-1992. Neurology. 1994 Oct;44(10):1892–900. Search in Google Scholar

6. Rachlis AR. (1998) Neurologic manifestations of HIV infection. Postgrad Med.;103:1–11. Search in Google Scholar

7. Institutul de Boli Infectioase “Prof. Dr. Matei Bals” Compartimentul pentru monitorizarea si evaluarea infectiei HIV/SIDA in Romania. Evolutia infectiei HIV/SIDA in Romania 31 Decembrie 2019. http://www.cnlas.ro/com_jce/date-statistice.html: Institutul de Boli Infectioase “Prof. Dr. Matei Bals”, 2019. Search in Google Scholar

8. Cohen C, Elion R, Ruane P, Shamblaw D, DeJesus E, Rashbaum B, et al. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS. 2011 Mar;25(6):F7-12 Search in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo